Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era

Coates, LC, O'Dwyer, J orcid.org/0000-0002-7212-6089, Meads, D et al. (3 more authors) (2022) Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era. The Lancet Rheumatology, 4 (6). E390-E391. ISSN 2665-9913

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2022 Elsevier Ltd. All rights reserved. This is an author produced version of a journal article published in The Lancet Rheumatology. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Accepted: 1 April 2022
  • Published (online): 13 April 2022
  • Published: June 2022
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Musculoskeletal Medicine & Imaging (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Health Sciences (Leeds) > Academic Unit of Health Economics (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 06 Apr 2022 13:57
Last Modified: 28 Jun 2022 10:32
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/S2665-9913(22)00101-1

Download

Accepted Version


Embargoed until: 13 October 2022

Filename: Accepted Doc (8).pdf

Licence: CC-BY-NC-ND 4.0

Request a copy

file not available

Share / Export

Statistics